Filter Search for grants
Call Navigation
Call key data
Call for proposals to support the development of a medicine pricing, reimbursement and access tracker through the EURIPID database
Funding Program
EU4Health programme 2021-2027
Call number
EU4H-2026-SANTE-PJ-06
deadlines
Opening
23.09.2025
Deadline
06.01.2026 17:00
Funding rate
60%
Call budget
€ 750,000.00
Estimated EU contribution per project
€ 750,000.00
Link to the call
Link to the submission
Call content
short description
This action will provide EURIPID members with a better overview of access, P&R measures and decisions across the Member States.
Call objectives
The objectives are to:
- measure and increase understanding of patient access to medicines in the Union;
- increase the quality of the database, in terms of timely/correct data delivery;
- expand the scope of the EURIPID members (to all the Member States) and data;
- leverage usefulness of the data beyond external reference pricing purposes.
Expected effects and impacts
In the longer term, it is expected to support mutual learning between national authorities and help the Member States in taking better pricing and reimbursement decisions, with a view to improve access, availability, and affordability of medicines. This is in line with the recommendations in the Draghi Report on the future of European competitiveness, and with the priority to ensure supply of affordable medicines, as outlined in the mission letter from Commission President von der Leyen to the Commissioner for Health and Animal Welfare.
The proposed “pricing and reimbursement (‘P&R’) tracker” and access dashboard will allow improved monitoring of patients’ access to medicines across the Union, including for cancer treatments. Having this data available prior to the application of the proposed pharmaceutical reform, will serve to measure the baseline and subsequently the impact of the proposed measures that aim to increase access to medicines across the Union, including for cancer treatments.
read more
Expected results
The objectives are to:
- measure and increase understanding of patient access to medicines in the Union;
- increase the quality of the database, in terms of timely/correct data delivery;
- expand the scope of the EURIPID members (to all the Member States) and data;
- leverage usefulness of the data beyond external reference pricing purposes.
Eligibility Criteria
Regions / countries for funding
Moldova (Moldova), Bosnia and Herzegovina (Bosna i Hercegovina / Босна и Херцеговина), Iceland (Ísland), Montenegro (Црна Гора), Norway (Norge), Ukraine (Україна)
eligible entities
Education and training institution, International organization, Non-Profit Organisation (NPO) / Non-Governmental Organisation (NGO), Other, Private institution, incl. private company (private for profit), Public Body (national, regional and local; incl. EGTCs), Research Institution incl. University, Small and medium-sized enterprise (SME)
Mandatory partnership
Yes
Project Partnership
In order to be eligible, the applicants (beneficiaries and affiliated entities) must:
- be legal entities (public or private bodies)
- be established in one of the eligible countries, i.e.:
- EU Member States (including overseas countries and territories (OCTs))
- listed EEA countries and countries associated to the EU4Health Programme (list of participating countries)
Proposals must be submitted by a consortium of at least 4 beneficiaries from 3 different eligible countries. Applicants should be EURIPID members, public authorities on pricing and reimbursement of medicines.
other eligibility criteria
Specific cases
- Natural persons are NOT eligible (with the exception of self-employed persons, i.e. sole traders, where the company does not have legal personality separate from that of the natural person).
- International organisations are eligible. The rules on eligible countries do not apply to them.
- Entities which do not have legal personality under their national law may exceptionally participate, provided that their representatives have the capacity to undertake legal obligations on their behalf, and offer guarantees for the protection of the EU financial interests equivalent to that offered by legal persons
- EU bodies (with the exception of the European Commission Joint Research Centre) can NOT be part of the consortium.
- Associations and interest groupings - entities composed of members may participate as ‘sole beneficiaries’ or ‘beneficiaries without legal personality’. Please note that if the action will be implemented by the members, they should also participate (either as beneficiaries or as affiliated entities, otherwise their costs will NOT be eligible).
- European Reference Networks (ERNs) — These cover networks between healthcare providers and centres of expertise in the Member States to reinforce healthcare cooperation, in particular in the area of rare diseases, in line with the objectives set out in Article 12 of Directive 2011/24.
- Countries currently negotiating association agreements — Beneficiaries from countries with ongoing negotiations for participation in the programme (see list of participating countries) may participate in the call and can sign grants if the negotiations are concluded before grant signature and if the association covers the call (i.e. is retroactive and covers both the part of the programme and the year when the call was launched).
- EU restrictive measures — Special rules apply for entities subject to EU restrictive measures under Article 29 of the Treaty on the European Union (TEU) and Article 215 of the Treaty on the Functioning of the EU (TFEU). Such entities are not eligible to participate in any capacity, including as beneficiaries, affiliated entities, associated partners, subcontractors or recipients of financial support to third parties (if any).
- EU conditionality measures — Special rules apply for entities subject to measures adopted on the basis of EU Regulation 2020/209214. Such entities are not eligible to participate in any funded role (beneficiaries, affiliated entities, subcontractors, recipients of financial support to third parties, etc). Currently such measures are in place for Hungarian public interest trusts established under the Hungarian Act IX of 2021 or any entity they maintain (see Council Implementing Decision (EU) 2022/2506, as of 16 December 2022).
Additional information
Topics
Relevance for EU Macro-Region
EUSAIR - EU Strategy for the Adriatic and Ionian Region, EUSALP - EU Strategy for the Alpine Space, EUSBSR - EU Strategy for the Baltic Sea Region, EUSDR - EU Strategy for the Danube Region
UN Sustainable Development Goals (UN-SDGs)
project duration
max. 36 months
Additional Information
Proposals must be submitted electronically via the Funding & Tenders Portal Electronic Submission System. Paper submissions are NOT possible.
Proposals must be complete and contain all the requested information and all required annexes and supporting documents:
- Application Form Part A — contains administrative information about the participants (future coordinator, beneficiaries and affiliated entities) and the summarised budget for the project (to be filled in directly online)
- Application Form Part B — contains the technical description of the project (template to be downloaded from the Portal Submission System, completed, assembled and re-uploaded)
- mandatory annexes and supporting documents (templates to be downloaded from the Portal Submission System, completed, assembled and re-uploaded):
- detailed budget table/calculator
- CVs (standard) of core project team
- list of previous projects (key projects for the last 4 years) (template available in Part B)
Proposals are limited to maximum 70 pages (Part B).
Financial support to third parties is not allowed.
Call documents
Call Document EU4H-2026-SANTE-PJCall Document EU4H-2026-SANTE-PJ(1036kB)
Contact
HaDEA-HP-CALLS@ec.europa.eu
Website
European Health and Digital Executive Agency - HaDEA - National Contact Points
Website
To see more information about this call, you can register for free here
or log in with an existing account.
Log in
Register now